Investors

Vysens B.V. is a Dutch company in the field of biomolecular interaction analysis (BIA); our first product is the CellVysion instrument.

Our system, CellVysion, is the first to measure true antibody–cell avidity in real time, under physiological conditions. This directly addresses a substatial market need, helping R&D teams select better leads and reduce trial failures.

We’ve made strong early progress: completed our first sale and have strong interest from leading pharma/CROs as beta customers.

We’re currently raising a seed round, and there is serious interest from a strategic investor to co-lead the round. We’re now opening the opportunity to select partners who can support our scale-up and commercial expansion.

Some points of interest:

  • Problem: Immunotherapy and antibody drug development are plagued by failures because current assays cannot measure true antibody–cell binding strength. In fact, 87.5% of immunotherapy trials fail (>$100M per failure) due to lack of avidity insight. Without real-time avidity data, researchers rely on costly trial-and-error and delayed drug validation.

  • Solution (CellVysion): Vysens’ CellVysion is the only platform that directly measures functional antibody–cell avidity in real time, live and label-free. It pinpoints the “tipping point” under controlled flow to quantify binding strength. By providing direct avidity metrics, CellVysion accelerates lead selection, reduces failed trials and lowers R&D costs.

  • Technology: CellVysion’s proprietary micro fluidic flow sensor and optics create a calibrated flow ramp over target cells, detecting the exact force at which antibodies detach. This generates a quantitative avidity score (from weak to strong binding) without labels or tags. The technology has been validated on various cell types (tumor, immune cells, RBCs), demonstrating reproducible binding strength ranging from ~7 to 610 pg/mm2 ligand density.

  • Market & Traction: There is growing demand in the CellVysion market for antibody R&D. CellVysion has early commercial traction: first system sold, 20 sales-qualified leads, 6 beta (“B-site”) installations underway, and >1,000 inbound leads. Top-tier biopharma and CROs are already engaged for pilots. Some major companies have explicitly positioned CellVysion to replace inferior methods, “how soon can we get CellVysion?”. This momentum validates broad interest for our solution.